BioNxt Solutions (TSE:BNXT)
:BNXT
Want to see TSE:BNXT full AI Analyst Report?
Top Page
BioNxt Solutions
(BNXT)
Select Model
Select Model
Rating:41Neutral
Price Target:
C$0.33
▼(-47.81% Downside)
Action:Reiterated
Date:06/02/26
The score is primarily constrained by very weak financial performance (zero revenue, sizable ongoing losses and cash burn, and a high-risk balance sheet with negative equity and meaningful debt). Technicals add downside pressure with price below all key moving averages and negative MACD. Valuation is not a clear positive because the company is loss-making (negative P/E) and no dividend yield is provided.
Positive Factors
Platform-based drug-delivery model
A platform strategy focused on reformulating existing APIs into patient-friendly delivery forms creates scalable commercial optionality and licensing revenue potential. Over months this reduces discovery risk, enabling partnerships that can fund development and offer recurring, higher-margin streams if adopted.
Negative Factors
Zero revenue and negative gross profit
Reporting effectively zero revenue and negative gross profit removes internal ability to scale or self-fund operations. Without product sales or licensing income, the company must rely on external financing to progress development, undermining sustainable commercial execution and partner leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Platform-based drug-delivery model
A platform strategy focused on reformulating existing APIs into patient-friendly delivery forms creates scalable commercial optionality and licensing revenue potential. Over months this reduces discovery risk, enabling partnerships that can fund development and offer recurring, higher-margin streams if adopted.
Read all positive factors
BioNxt Solutions (BNXT) vs. iShares MSCI Canada ETF (EWC)
Market Cap
C$45.49M
Dividend YieldN/A
Average Volume (3M)80.86K
Price to Earnings (P/E)―
Beta (1Y)0.28
Revenue Growth-62.34%
EPS Growth9.80%
CountryCA
Employees25
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.08
Shares Outstanding129,959,350
10 Day Avg. Volume59,081
30 Day Avg. Volume80,860
Financial Highlights & Ratios
PEG Ratio-0.44
Price to Book (P/B)-8.07
Price to Sales (P/S)0.00
P/FCF Ratio-14.55
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BioNxt Solutions Business Overview & Revenue Model
Company Description
Headquartered in Vancouver, Canada, BioNxt Solutions Inc., established in 2017, operates as a bioscience company across Germany, Switzerland, Austria, Israel, and its home country. The firm focuses on developing innovative drug delivery systems, i...
How the Company Makes Money
null...
BioNxt Solutions Financial Statement Overview
Summary
Income Statement
7
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
10
Very Negative
| Breakdown | Mar 2026 | Mar 2025 | Mar 2024 | Dec 2022 | Mar 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 26.98K | 372.25K | 297.44K | 286.50K |
| Gross Profit | -10.90K | 26.98K | 372.25K | 195.62K | 199.48K |
| EBITDA | -6.04M | -4.32M | -6.48M | -11.51M | -19.19M |
| Net Income | -7.03M | -5.31M | -7.72M | -12.38M | -20.64M |
Balance Sheet | |||||
| Total Assets | 591.68K | 569.36K | 1.27M | 1.61M | 9.73M |
| Cash, Cash Equivalents and Short-Term Investments | 55.26K | 32.35K | 363.65K | 136.20K | 1.35M |
| Total Debt | 5.95M | 4.28M | 4.89M | 4.37M | 5.46M |
| Total Liabilities | 9.96M | 8.43M | 6.55M | 5.74M | 8.06M |
| Stockholders Equity | -9.37M | -7.86M | -5.28M | -4.13M | 1.67M |
Cash Flow | |||||
| Free Cash Flow | -5.20M | -3.03M | -5.37M | -6.23M | -12.61M |
| Operating Cash Flow | -5.20M | -3.03M | -5.17M | -6.23M | -12.16M |
| Investing Cash Flow | 87.43K | 56.21K | 100.84K | -3.86K | -5.31M |
| Financing Cash Flow | 5.13M | 2.64M | 5.29M | 5.02M | 16.23M |
BioNxt Solutions Technical Analysis
Negative
0.64
Price Trends
0.44
Negative
0.51
Negative
0.62
Negative
Market Momentum
-0.02
Positive
38.52
Neutral
26.54
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BNXT, the sentiment is Negative. The current price of 0.64 is above the 20-day moving average (MA) of 0.40, above the 50-day MA of 0.44, and above the 200-day MA of 0.62, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 38.52 is Neutral, neither overbought nor oversold. The STOCH value of 26.54 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BNXT.
BioNxt Solutions Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | C$29.74M | -3.40 | -19.10% | ― | 0.66% | -14.29% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | C$56.36M | -0.76 | -19.76% | ― | -100.00% | 87.93% | |
44 Neutral | C$14.17M | -6.69 | -71.80% | ― | -17.50% | -120.67% | |
41 Neutral | C$45.49M | -4.72 | ― | ― | -62.34% | 9.80% | |
41 Neutral | C$16.35M | -4.31 | -68.32% | ― | 1.96% | -24.60% |
* Healthcare Sector Average
TSE:BNXT
BioNxt Solutions
0.35
-0.20
-36.36%
TSE:ATLE
Willow Biosciences Inc
0.16
-0.01
-8.57%
TSE:QNTM
Quantum Biopharma
5.43
-42.61
-88.70%
TSE:LABS
MediPharm Labs
0.07
>-0.01
-6.67%
TSE:AVCN
Avicanna
0.13
-0.14
-51.85%
TSE:INNO
InnoCan Pharma
3.15
-11.80
-78.93%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.